GlassScriptPhysician profile
Yara Cabrera
NPI 1487154316
$4,672.25
in general payments reported to CMS, 2019-2025
31 companies · $902 in 2025
The $902 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $854 · 2023: $1,445 · 2024: $928 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.86 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $813.27 | 2021-2025 | Gentlecath, Gentlecath Glide, Cure Catheter |
| Sumitomo Pharma America, INC. | $614.38 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $596.01 | 2021-2024 | Myrbetriq, Xtandi |
| Pfizer INC. | $479.68 | 2021-2025 | |
| Blue Earth Diagnostics | $360.95 | 2021-2025 | Posluma |
| Myriad Genetic Laboratories, INC. | $281.27 | 2022-2025 | Prolaris, Myrisk |
| Janssen Biotech, INC. | $254.38 | 2022-2025 | Erleada |
| Abbvie INC. | $178.69 | 2022-2025 | |
| Axonics, INC. | $134.53 | 2021 | |
| Urovant Sciences INC | $131.85 | 2021-2022 | |
| Tolmar, INC. | $86.65 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $71.74 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $65.89 | 2024-2025 | |
| Myovant Sciences INC. | $64.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.94 | 2021-2023 | Lynparza, Keytruda |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $61.54 | 2021-2022 | |
| Urogen Pharma, INC. | $61.19 | 2023-2024 | Jelmyto |
| Biotissue Holdings INC. | $56.54 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $54.40 | 2024-2025 | Bard Urinary Drainage Bag |
| Endo USA, INC. | $30.62 | 2025 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $26.80 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.49 | 2024 | Oxlumo |
| Alfasigma USA, INC. | $21.71 | 2022 | |
| Dendreon Pharmaceuticals LLC | $19.76 | 2025 | Provenge |
| Coloplast Corp | $19.09 | 2023 | Speedicath |
| Exact Sciences Corporation | $18.61 | 2024 | Cologuard Collection Kit |
| Convatec INC. | $17.32 | 2021 | |
| Boston Scientific Corporation | $17.06 | 2024 | Spaceoar Vue System - 10ml |
| Telix Pharmaceuticals | $16.98 | 2023 | Illuccix |
| Verona Pharma, INC. | $15.05 | 2025 | Ohtuvayre |
| Philips North America LLC | $13.66 | 2025 | Uronav |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yara Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.